Frederick Stehman

  • 7000 Citations
  • 38 h-Index
1978 …2017
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 14 Similar Profiles
Carcinoma Medicine & Life Sciences
Uterine Cervical Neoplasms Medicine & Life Sciences
Cervix Uteri Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences
Vulva Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Ovarian Neoplasms Medicine & Life Sciences
Cisplatin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

NIH Grants 1978 1989

GYNECOLOGIC ONCOLOGY GROUP-INDIANA UNIVERSITY

Stehman, F. & Ehrlich, C. E.

National Institutes of Health

7/1/786/30/89

Project: Research project

patient care
research projects
therapeutics
neoplasms
methodology

Publications 1979 2017

  • 7000 Citations
  • 38 h-Index
  • 130 Article
  • 4 Chapter
5 Citations (Scopus)

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience

Oliver, K. E., Brady, W. E., Birrer, M., Gershenson, D. M., Fleming, G., Copeland, L. J., Tewari, K., Argenta, P. A., Mannel, R. S., Secord, A. A., Stephan, J. M., Mutch, D. G., Stehman, F., Muggia, F. M., Rose, P. G., Armstrong, D. K., Bookman, M. A., Burger, R. A. & Farley, J. H., 2017, (Accepted/In press) In : Gynecologic Oncology.

Research output: Contribution to journalArticle

Platinum
Ovarian Neoplasms
Disease-Free Survival
Carcinoma
Survival
36 Citations (Scopus)

Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Tewari, K. S., Sill, M. W., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., Michael, H., DiSaia, P. J., Copeland, L. J., Creasman, W. T., Stehman, F., Brady, M. F., Burger, R. A., Thigpen, J. T., Birrer, M. J., Waggoner, S. E., Moore, D. H. & 3 othersLook, K. Y., Koh, W. J. & Monk, B. J., 2017, (Accepted/In press) In : The Lancet.

Research output: Contribution to journalArticle

Uterine Cervical Neoplasms
Drug Therapy
Survival
Fistula
Paclitaxel
1 Citation (Scopus)

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Rose, P. G., Java, J. J., Morgan, M. A., Alvarez-Secord, A., Kesterson, J. P., Stehman, F., Warshal, D. P., Creasman, W. T., Hanjani, P., Morris, R. T. & Copeland, L. J., 2016, In : Gynecologic Oncology. 143, 3, p. 511-515 5 p.

Research output: Contribution to journalArticle

Ovarian Neoplasms
Disease-Free Survival
Survival
Operative Surgical Procedures
Residual Neoplasm
12 Citations (Scopus)

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis

Moore, K. N., Java, J. J., Slaughter, K. N., Rose, P. G., Lanciano, R., DiSilvestro, P. A., Thigpen, J. T., Lee, Y. C., Tewari, K. S., Chino, J., Seward, S. M., Miller, D. S., Salani, R., Moore, D. H. & Stehman, F., Nov 1 2016, In : Gynecologic Oncology. 143, 2, p. 294-301 8 p.

Research output: Contribution to journalArticle

Uterine Cervical Neoplasms
Biomarkers
Radiation
Survival
Brachytherapy
32 Citations (Scopus)
Nomograms
Chemoradiotherapy
Uterine Cervical Neoplasms
Disease-Free Survival
Recurrence